State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Move strengthens footprint in Western India and expands multi-specialty care network
Focus on preventive, tech-driven healthcare and digital ecosystem reforms under AB PM-JAY and ABDM
Dr Shivkumar Kalyanaraman emphasizes need for quality research, partnerships, and measurable outcomes
Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk
Bidding window open till May 15; study to map costs and bottlenecks across pharma supply chains
Among his notable contributions is the development of the NAGI Stent, a widely adopted device for the drainage of pancreatic pseudocysts
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
Subscribe To Our Newsletter & Stay Updated
